Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07406542CT.gov A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07461454CT.gov YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06875128CT.gov Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease | — | Recruiting | — | — | — |
NCT07540533CT.gov A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07007559CT.gov ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer | — | Recruiting | — | — | — |
NCT06102824CT.gov Organoid-based Functional Precision Therapy for Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05933395CT.gov Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor | — | Recruiting | — | — | — |
NCT06383767CT.gov A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT05919108CT.gov Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | — | Recruiting | — | — | — |
NCT06229067CT.gov Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
Show 134 more trialsShow fewer
NCT06268652CT.gov Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | — | Recruiting | — | — | — |
NCT06375707CT.gov Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer | — | Unknown | — | — | — |
NCT06176534CT.gov Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial | — | Recruiting | — | — | — |
NCT06079983CT.gov JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | — | Recruiting | — | — | — |
NCT06081959CT.gov Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06099769CT.gov A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06143553CT.gov Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT04901299CT.gov Fulvestrant + Neratinib In Breast Cancer | — | Withdrawn | — | — | — |
NCT05876065CT.gov Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06202261CT.gov A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT06373744CT.gov Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients | — | Completed | — | — | — |
NCT05594095CT.gov SNF Platform Study of HR+/ HER2-advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05388149CT.gov Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | — | Recruiting | — | — | — |
NCT06015126CT.gov Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients | — | Unknown | — | — | — |
NCT05491057CT.gov Treatment Patterns of Neratinib in HER2+ EBC in China | — | Not Yet Recruiting | — | — | — |
NCT05252988CT.gov Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib | — | Active Not Recruiting | — | — | — |
NCT05243641CT.gov Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test | — | Terminated | — | — | — |
NCT04886531CT.gov Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | — | Recruiting | — | — | — |
NCT05296577CT.gov Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer | — | Unknown | — | — | — |
NCT05823623CT.gov Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT05747326CT.gov Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer | — | Unknown | — | — | — |
NCT04856475CT.gov Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer | — | Withdrawn | — | — | — |
NCT05104866CT.gov A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | — | Active Not Recruiting | — | — | — |
NCT05346861CT.gov Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab | — | Unknown | — | — | — |
NCT05063786CT.gov Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | — | Active Not Recruiting | — | — | — |
NCT04963595CT.gov Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer | — | Unknown | — | — | — |
NCT04922008CT.gov Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D) | — | Not Yet Recruiting | — | — | — |
NCT04759248CT.gov Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04665986CT.gov Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer | — | Unknown | — | — | — |
NCT05131841CT.gov Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC | — | Unknown | — | — | — |
NCT04639986CT.gov Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | — | Active Not Recruiting | — | — | — |
NCT04400695CT.gov A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 | — | Unknown | — | — | — |
NCT04681911CT.gov Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT04605575CT.gov Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04389073CT.gov Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine | — | Unknown | — | — | — |
NCT04262804CT.gov A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | — | Unknown | — | — | — |
NCT04265274CT.gov Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. | — | Withdrawn | — | — | — |
NCT03997539CT.gov A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT03812393CT.gov Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast | — | Unknown | — | — | — |
NCT03901339CT.gov Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03839823CT.gov Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03933982CT.gov A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT03094052CT.gov Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | — | Completed | — | — | — |
NCT03414658CT.gov The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03518606CT.gov Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours | — | Completed | — | — | — |
NCT03101748CT.gov Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT03393741CT.gov Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy | — | Terminated | — | — | — |
NCT03321981CT.gov MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. | — | Completed | — | — | — |
NCT03377387CT.gov Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02574455CT.gov Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) | — | Completed | — | — | — |
NCT03289039CT.gov Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03032614CT.gov Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients | — | Withdrawn | — | — | — |
NCT02658084CT.gov Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03182634CT.gov The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | — | Unknown | — | — | — |
NCT02673398CT.gov Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT02915744CT.gov A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | — | Completed | — | — | — |
NCT02595905CT.gov Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases | — | Completed | — | — | — |
NCT02768415CT.gov Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer | — | Unknown | — | — | — |
NCT03006614CT.gov PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer | — | Unknown | — | — | — |
NCT02628613CT.gov Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations | — | Completed | — | — | — |
NCT02344472CT.gov Detect V / CHEVENDO (Chemo vs. Endo) | — | Active Not Recruiting | — | — | — |
NCT02331251CT.gov Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | — | Terminated | — | — | — |
NCT02236000CT.gov A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT02213744CT.gov MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | — | Terminated | — | — | — |
NCT02163694CT.gov A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | — | Completed | — | — | — |
NCT02033551CT.gov A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT02225470CT.gov Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | — | Completed | — | — | — |
NCT01950182CT.gov Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer | — | Completed | — | — | — |
NCT01618357CT.gov Pre-Operative Radiation and Veliparib for Breast Cancer | — | Completed | — | — | — |
NCT01818063CT.gov Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | — | Completed | — | — | — |
NCT01853306CT.gov A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT01802970CT.gov Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients | — | Completed | — | — | — |
NCT01730677CT.gov Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab | — | Unknown | — | — | — |
NCT01941771CT.gov Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01506609CT.gov Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01477489CT.gov Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer | — | Completed | — | — | — |
NCT01492101CT.gov The BEACON Study (Breast Cancer Outcomes With NKTR-102) | — | Completed | — | — | — |
NCT01528826CT.gov Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial | — | Unknown | — | — | — |
NCT01137994CT.gov A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT01351909CT.gov Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01423123CT.gov Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer | — | Completed | — | — | — |
NCT01281150CT.gov Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT01251874CT.gov Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01008150CT.gov Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | — | Completed | — | — | — |
NCT01254136CT.gov Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer | — | Terminated | — | — | — |
NCT01238029CT.gov Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01233505CT.gov Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT01161368CT.gov A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients | — | Terminated | — | — | — |
NCT01156753CT.gov A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer | — | Completed | — | — | — |
NCT01104259CT.gov Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01149083CT.gov Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer | — | Completed | — | — | — |
NCT01145430CT.gov Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01155258CT.gov Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT01111825CT.gov Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT01042379CT.gov I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | — | Recruiting | — | — | — |
NCT01060514CT.gov Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer | — | Terminated | — | — | — |
NCT01007942CT.gov Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00915018CT.gov Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT00878709CT.gov Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00777101CT.gov Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT00741260CT.gov Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | — | Completed | — | — | — |
NCT00912275CT.gov Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00828074CT.gov Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00754702CT.gov Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00795678CT.gov Chemotherapeutic Agents in Brain/Breast | — | Completed | — | — | — |
NCT00709618CT.gov Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects | — | Terminated | — | — | — |
NCT00776724CT.gov Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm | — | Completed | — | — | — |
NCT00708903CT.gov Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization) | — | Completed | — | — | — |
NCT00706030CT.gov Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00503750CT.gov Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™) | — | Completed | — | — | — |
NCT00764972CT.gov Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00629148CT.gov Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC) | — | Completed | — | — | — |
NCT00513058CT.gov Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00372476CT.gov Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00278070CT.gov Metronomic Oral Vinorelbine in Patients With Metastatic Tumors | — | Completed | — | — | — |
NCT00266110CT.gov Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00140140CT.gov A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer | — | Terminated | — | — | — |
NCT00194792CT.gov Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer | — | Terminated | — | — | — |
NCT01439191CT.gov Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00532623CT.gov Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00088985CT.gov Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00148668CT.gov Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer | — | Completed | — | — | — |
NCT00075673CT.gov Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00159094CT.gov A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00544765CT.gov Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer | — | Completed | — | — | — |
NCT00169104CT.gov Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function | — | Terminated | — | — | — |
NCT00153907CT.gov Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00148681CT.gov Preoperative Herceptin and Navelbine for Breast Cancer | — | Completed | — | — | — |
NCT00006682CT.gov Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00001944CT.gov Vinorelbine and XR9576 to Treat Cancer | — | Completed | — | — | — |
NCT00014430CT.gov Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer | — | Completed | — | — | — |
NCT00004237CT.gov Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vinorelbine Ditartrate (this asset) | CSPC Megalith Biopharmaceutical Co.,Ltd. | Approved | BB · 67 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Vinorelbine Ditartrate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hodgkins Lymphoma | — | P3 | BBB · 72 |
| Cervical Cancer | — | P2 | BBB · 72 |
| Lung Large Cell Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vinorelbine Ditartrate in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vinorelbine-ditartrate-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →